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We investigated whether serum aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) could predict severe
cases of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) based on the Birmingham vasculitis activity
score (BVAS). Sixty-one patients with AAV were selected for inclusion from our prospective AAV cohort. AAV-specific indices
and clinical manifestations were assessed, and laboratory tests were performed on the day of blood sampling. Patients with severe
AAV were defined as those with a BVAS higher than the lower limit of the highest tertile of BVAS (BVAS ≥ 12). We measured
serum AIMP1 levels of the stored serum samples. A total of 20 (32.8%) and 41 (67.2%) patients were classified as having severe
and nonsevere AAV according to the cut-off of BVAS ≥ 12. Patients with severe AAV showed higher frequencies of general and
renal manifestations, along with ANCA positivity, and exhibited a higher mean neutrophil count, erythrocyte sedimentation rate,
and C-reactive protein levels, but lower mean haemoglobin and serum albumin levels than those with nonsevere AAV.The mean
serum AIMP1 level in patients with severe AAV was significantly higher than that of patients with nonsevere AIMP1 (351.1 vs. 98.4
pg/mL, p = 0.006). Multivariate logistic regression analysis including variables showing significance in univariate analyses revealed
that only serum AIMP1 exhibited a significant association with severe AAV (odds ratio 1.004, p = 0.031). When we set the optimal
cut-off of serum AIMP1 for severe AAV to 50.28 pg/mL, patients with severe AAV more frequently had AIMP1 levels above the
cut-off than those with nonsevere AAV (80.0% vs. 31.7%, relative risk 8.615, p < 0.001). The results from our study suggest that
serum AIMP1 can be used to estimate the cross-sectional severe AAV population based on the BVAS.
1. Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is characterized by necrotising vasculitis
in small-sized vessels and is categorized into three vari-
ants: microscopic polyangiitis (MPA), granulomatosis with
polyangiitis (GPA), and eosinophilic granulomatosis with
polyangiitis (EGPA), based on the 2012 Chapel Hill Con-
sensus Conferences (CHCC) Nomenclature of Vasculitis
[1]. Activated macrophages secrete several proinflamma-
tory cytokines such as tumour-necrosis factor (TNF)-𝛼,
interleukin (IL)-1𝛽, and IL-6, which prime neutrophils to
subsequently release myeloperoxidase (MPO) or proteinase
3 (PR3). The secreted MPO and PR3 can be recognized by
antigen-presenting cells and presented to helper T cells, lead-
ing to the production of anti-MPO or anti-PR3 ANCAs by B
cells [2]. ANCA-mediated activation of primed neutrophils
provokes bulky inflammation on the vessel walls as well as in
their adjacent tissues [3].Thus, AAVmay be triggered by both
proinflammatory cytokines and autoreactive immune cells.
Aminoacyl-tRNA synthetase (ARS)-interacting multi-
functional protein-1 (AIMP1) is one of the three nonenzy-
matic factors assembling a multi-tRNA synthetase complex
with 11 different ARSs [4]. AIMP1 can also be secreted
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and may modulate the immune reaction by enhancing the
production of proinflammatory cytokines such as TNF-𝛼,
IL-6, IL-8, and IL-12 by activated immune cells [5]. Thus,
AIMP1 may participate in the pathogenesis of autoimmune
diseases, especially AAV. We previously demonstrated the
clinical potential of AIMP1 as a biomarker in patients with
rheumatoid arthritis and systemic lupus erythematosus (SLE)
[6, 7]. However, there is no report regarding the clinical role
of serumAIMP1 in AAV. Hence, in this study, we investigated
whether serum AIMP1 could be used to estimate the cross-
sectional severity of AAV patients based on the Birmingham
vasculitis activity score (BVAS) in a prospective cohort of
AAV patients [8].
2. Materials and Methods
2.1. Patients, Clinical and Laboratory Data, and Serum AIMP1
Measurement. This study included 61 patients diagnosed
with AAV selected among our prospective Severance Hos-
pital ANCA-associated VasculitidEs (SHAVE) cohort. All
patients were first diagnosed with AAV in the Department
of Rheumatology, Yonsei University College of Medicine,
Severance Hospital, from October 2000 to July 2018, and
classified based on the 2007 European Medicines Agency
algorithms and the 2012 CHCC Nomenclature of Vasculitis
[1, 9]. On the day of blood sampling, patients with serious
medical conditions other than AAV, such as serious infection
or malignancies, were excluded from the study. This study
was approved by the Institutional Review Board of Severance
Hospital (4-2016-0901), and all patients provided written
informed consent at the time of blood sampling.
On the day of blood sampling, the BVAS [8], five-
factor score (FFS) (2009) [10], vasculitis damage index (VDI)
[11], Korean version of the short form-36 (SF-36) [12], and
clinical manifestations were assessed and laboratory tests
were performed. Because the BVAS for GPA is determined
according to a different weight system, we evenly applied the
BVAS to patients with both MPA and GPA so as to unify the
scoring system. We stratified AAV patients into three groups
according to the tertile of BVAS, in which patients with a
BVAS higher than the lower limit of the highest tertile (BVAS
≥ 12) were considered to have severe AAV. We also counted
the number of patients under treatment with immunosup-
pressive drugs. We obtained whole blood samples from each
patient with AAV, isolated the serum, and stored it at –80∘C
until analysis. AIMP1 levels were determined with human
AIMP1 enzyme-linked immunoassay kits purchased from
Cloud-Clone Corp. (Houston, TX, USA) according to the
manufacturer’s instructions [7].
2.2. Statistical Analyses. All statistical analyses were con-
ducted using SPSS software (version 23 for windows; IBM
Corp., Armonk, NY, USA). Differences in variables between
the two groups (severe and nonsevere AAV) were analyzed
using the chi-squared and Fisher’s exact tests or the Mann-
Whitney U test. The odds ratio (OR) was assessed using
multivariate logistic regression analysis of variables with p-
values less than 0.05 in univariate logistic regression analysis.
The optimal cut-off of serum AIMP1 for severe AAV was
extrapolated by constructing the receiver operator charac-
teristic (ROC) curve. The relative risk of the optimal cut-off
value of serum AIMP1 for severe AAV was analyzed using
contingency tables and the chi-squared test. P-values less than
0.05 were considered statistically significant.
3. Results
3.1. Comparison of Clinical Characteristics in Patients with
and without Severe AAV. The baseline characteristics of the
61 patients with AAV are described in Table 1, including 20
(32.8%) and 41 (67.2%) patients classified as having severe
and nonsevere AAV, respectively. No significant differences
were found concerning the variants of AAVand demographic
data between the groups, except for the higher proportion of
patients with new-onset AAV in the severe group (65.0% vs.
26.8%, p = 0.005). Patients with severe AAV exhibited higher
mean BVAS and FFS (2009) than those without (p = 0.009).
In addition, general and renal manifestations were more
commonly observed and ANCA positivity was more often
detected in patients with severe AAV. With respect to the
routine laboratory results, patientswith severeAAVexhibited
a higher mean neutrophil count, erythrocyte sedimentation
rate (ESR), and C-reactive protein (CRP) level, but showed
lower mean haemoglobin and serum albumin levels than
those without. There was also a lower proportion of patients
on prednisolone treatment in the severe AAV group owing to
the higher rate of new-onset AAV among these patients. The
mean level of serum AIMP1 in patients with severe AAV was
significantly higher than in those without (Table 1).
3.2. Logistic Regression Analysis. Baseline ANCA positivity
and laboratory data with statistical significance were subse-
quently included in the univariate and multivariate logistic
regression analysis.We excluded the FFS (2009) in the logistic
regression analysis due to the similarity of its constituent
items to those used to calculate the BVAS. In the multivariate
logistic regression analysis, only serum AIMP1 exhibited a
significant association with severe AAV (Table 2).
3.3. Optimal Cut-Oﬀ of Serum AIMP1 and Its Relative Risk for
Severe AAV. The optimal cut-off level of serum AIMP1 for
predicting severe AAV was determined to be 50.28 pg/mL
based on the area under the ROC curve (0.757, 95% CI
0.625–0.890; sensitivity 0.800, specificity 0.683; Supplemen-
tary Figure S1). That is, severe AAV was more frequently
identified in patients with a serumAIMP1 level≥50.28 pg/mL
than in those with a serum AIMP1 level <50.28 pg/mL
(relative risk, 8.615; 95%CI: 2.400–30.923, p< 0.001; Figure 1).
4. Discussion
In this study, we investigated the clinical value of serum
AIMP1 in stratifyingAAVpatients according to disease sever-
ity and demonstrated that serumAIMP1 could independently
be used for cross-sectional classification of patients into
severe and nonsevere AAV based on the BVAS.
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Table 1: Comparison of variables between patients with and without severe AAV.
Patients with
severe AAV
(n=20)
Patients without
severe AAV
(n=41)
p-value
Variants (N, (%))
MPA 12 (60.0) 20 (48.8) 0.414
GPA 7 (35.0) 11 (26.8) 0.515
EGPA 1 (5.0) 10 (24.4) 0.084
Demographic data
Age (years) 63.2 ± 14.4 57.6 ± 14.0 0.153
Female gender (N, (%)) 14 (70.0) 26 (63.4) 0.614
Disease duration (months) 10.8 ± 28.3 27.5 ± 47.8 0.093
New onset AAV 13 (65.0) 11 (26.8) 0.005
AAV-speciﬁc indices
BVAS 17.4 ± 4.1 4.9 ± 3.0 <0.001
FFS (2009) 1.8 ± 1.0 1.1 ± 0.9 0.009
VDI 3.4 ± 1.5 3.0 ± 1.8 0.419
SF-36 PCS score 43.1 ± 20.0 53.3 ± 23.3 0.097
SF-36MCS score 55.1 ± 19.4 59.3 ± 20.7 0.457
Clinical features (N, (%))
General 10 (50.0) 7 (17.1) 0.008
Cutaneous 2 (10.0) 5 (12.2) 0.999
Mucous membrane and eye 1 (5.0) 2 (4.9) 0.999
Ear, nose, and throat 8 (40.0) 17 (41.5) 0.914
Pulmonary 16 (80.0) 22 (53.7) 0.055
Cardiovascular 1 (5.0) 2 (4.9) 0.999
Abdominal 1 (5.0) 0 (0.0) 0.328
Renal 17 (85.0) 17 (41.5) 0.002
Nervous system 4 (20.0) 8 (19.5) 0.999
ANCA positivity (N, (%))
ANCA double positive 0 (0.0) 1 (2.4) 0.999
MPO-ANCA or P-ANCA positive 16 (80.0) 21 (51.2) 0.050
PR3-ANCA or C-ANCA positive 2 (10.0) 5 (12.2) 0.999
ANCA positivity 18 (90.0) 25 (61.0) 0.020
MPO titre (Units/mL) 52.8 ± 49.7 23.1 ± 41.6 0.017
PR3 titre (Units/mL) 1.6 ± 4.8 1.0 ± 4.3 0.637
Laboratory data
White blood cell count (/mm3) 9,437.5 ± 4,008.4 7,733.9 ± 3,367.8 0.087
Neutrophil count (/mm3) 7,763.5 ± 3,642.9 5,196.5 ± 3,065.2 0.006
Haemoglobin (g/dL) 10.0 ± 2.2 12.6 ± 1.7 <0.001
Platelet count (× 1,000/mm3) 299.7 ± 129.5 271.5 ± 79.1 0.379
Creatinine (mg/dL) 2.4 ± 1.8 1.5 ± 1.9 0.093
Serum albumin (g/dL) 3.3 ± 0.6 4.0 ± 0.5 <0.001
AST (IU/L) 19.4 ± 7.9 22.5 ± 16.9 0.331
ALT (IU/L) 23.0 ± 14.6 20.8 ± 13.6 0.575
ESR (mm/hr) 55.5 ± 44.5 32.9 ± 21.5 0.042
CRP (mg/L) 29.0 ± 41.4 3.5 ± 5.7 0.013
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Table 1: Continued.
Patients with
severe AAV
(n=20)
Patients without
severe AAV
(n=41)
p-value
Immunosuppressive drugs (N, (%))
Prednisolone 10 (50.0) 33 (80.5) 0.014
Cyclophosphamide 4 (20.0) 5 (12.2) 0.420
Rituximab 1 (5.0) 0 (0) 0.149
Azathioprine 2 (10.0) 12 (29.3) 0.093
Tacrolimus 0 (0) 3 (7.3) 0.215
Mycophenolate mofetil 0 (0) 2 (4.9) 0.315
Methotrexate 1 (5.0) 1 (2.4) 0.598
Novel serum biomarker
Serum AIMP1 (ng/mL) 351.1 ± 350.9 98.4 ± 67.9 0.006
Values are expressed as mean ± standard deviation or number (percentages).
AAV:ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody;MPA:microscopic polyangiitis; GPA: granulomatosis with polyangiitis; EGPA:
eosinophilic granulomatosis with polyangiitis; BVAS: Birmingham vasculitis activity score; FFS: five-factor score; VDI: vasculitis damage index; SF-36: short
form-36; PCS: physical component summary; MCS: mental component summary; MPO: myeloperoxidase; P: perinuclear; PR3: proteinase 3; C: cytoplasmic;
AST: aspartate aminotransferase; ALT: alanine aminotransferase; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; AIMP1: aminoacyl-tRNA
synthetase-interacting multifunctional protein-1.
Table 2: Univariate and multivariate logistic regression analyses of laboratory variables with significance for prediction of severe AAV.
Univariate analysis Multivariate analysis
Odds ratio 95% CI p-value Odds ratio 95% CI p-value
Laboratory variables
ANCA positivity 5.760 1.175, 28.244 0.031 1.075 0.137, 8.416 0.945
Neutrophil count 1.000 1.000, 1.000 0.010 1.000 1.000, 1.000 0.967
Haemoglobin 0.511 0.360, 0.726 <0.001 0.616 0.368, 1.029 0.064
Serum albumin 0.069 0.015, 0.315 0.001 0.349 0.038, 3.203 0.352
ESR 1.022 1.004, 1.040 0.016 0.981 0.947, 1.015 0.272
CRP 1.070 1.005, 1.139 0.034 1.087 0.955, 1.238 0.207
Serum AIMP1 1.004 1.001, 1.006 0.003 1.004 1.000, 1.008 0.031
AAV:ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; CI: confidence interval; ESR: erythrocyte sedimentation rate; CRP: C-reactive
protein; AIMP1: aminoacyl-tRNA synthetase-interacting multifunctional protein-1.
Proinflammatory cytokines have been reported to be
involved in the pathogenesis of AAV, including TNF-𝛼, IL-1𝛽,
IL-6, IL-8, and IL-12 [7, 13]. SecretedAIMP1was also reported
to enhance the serum concentration of these cytokines [5].
Thus, this connection between the pathogenesis of AAV
and the inflammatory action of secreted AIMP1 led us to
speculate that serum AIMP1 would be a valuable marker to
categorize patients at risk of severe AAV based on the BVAS.
However, we could not clarify the direct correlation between
serum AIMP1 and proinflammatory cytokines, as described
in a previous report [13].
Despite substantial progress in understanding the patho-
genesis of AAV, there is still no reliable biomarker to assess
disease activity in AAV. As such, inflammatory factors such
as ESR, CRP, and alterations of ANCA titres are still the
most commonly used markers to assess disease activity in
clinical practice. Here, we found that BVAS was significantly
correlated with ESR, CRP, and AIMP1; however, the serum
AIMP1 level was not correlated with ESR (p = 0.071) or
CRP (p = 0.220). A previous study demonstrated that the
correlation of major AAV-specific cytokines and ESR or CRP
was relatively low [13]. Thus, we assume that serum AIMP1
could be used to estimate the cross-section of patients with
severe AAV via intracellular signals, which could differ from
the factors influencing ESR and CRP levels. Importantly, in
this study, serum AIMP1 was significantly associated with
severe AAV irrespective of ESR, CRP, and ANCA titres.
Therefore, the clinical utility of serum AIMP1 could be
emphasized by the fact that it could serve as a complementary
index for predicting severe AAV, independently of ESR, CRP,
and ANCA levels.
In our previous study, the cut-off level of serum AIMP1
for predicting active SLE was 10.09 ng/mL, which is about
200 times higher than the cut-off for predicting severe AAV
determined in the present study (50.28 pg/mL). Further-
more, the mean serum AIMP1 level in patients with severe
AAV was much lower than that in patients with active
SLE (351.1 pg/mL vs. 8,000.0 pg/mL) [7]. Although we did
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Figure 1: Relative risk of severe AAV based on the optimal cut-oﬀ
of serum AIMP1 (50.28 pg/mL). AAV: ANCA-associated vasculitis;
AIMP1: aminoacyl-tRNA synthetase-interacting multifunctional
protein-1; RR: relative risk.
not include patients with SLE in the present study, and
thus could not directly compare serum AIMP1 between the
two diseases, these results suggest that the dynamic range
of the serum concentration of AIMP1 to estimate disease
severity might be autoimmune disease-specific. Thus, the
underlying autoimmune disease should be considered when
determining cut-offs of serum AIMP1 to define high disease
activity.
As a pilot study, this study has a strength in that it is the
first demonstration of the clinical value of serum AIMP1 as a
marker for cross-sectional analyses of severe and nonsevere
AAV cases in the prospective SHAVE cohort, which includes
clinical and laboratory data and blood samples collected on
the same day. However, our study also has several limitations.
First, the number of patients was not sufficiently large to
represent the general Korean patient population with AAV
or to conduct subgroup analyses due to the monocentric
study design. Second, we could not serially measure serum
AIMP1 levels in each AAV patient. Third, we could not clarify
the correlation between serum AIMP1 and proinflammatory
cytokines by measuring serum proinflammatory cytokine
levels. Fourth, we were not able to measure serum AIMP1
levels in healthy subjects for comparison. Future studies
with a larger number of AAV patients in the prospec-
tive SHAVE cohort and serially measured parameters will
provide more reliable and validated information on the
clinical implications of serum AIMP1 for stratifying AAV
patients.
5. Conclusions
In conclusion, we have demonstrated that serum AIMP1 can
be used as an estimate for cross-sectional analysis of severe
AAV based on the BVAS. Thus, measuring serum AIMP1
might provide useful information regarding disease activity
for monitoring patients with AAV.
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